What is the new drug for heart inflammation?: A Look at Colchicine and Emerging Therapies
•
3 min read
In 2023, the U.S. Food and Drug Administration (FDA) approved Lodoco (colchicine) as the first anti-inflammatory drug specifically for cardiovascular disease, a significant development in treating heart inflammation. This groundbreaking approval addresses the long-known role of inflammation in driving heart attacks and strokes, offering a new treatment avenue for high-risk patients in addition to standard care. While colchicine is a repurposed drug with a new indication, exciting research continues into novel therapies for conditions like myocarditis and recurrent pericarditis.
